Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HMO Claims Study Will Provide Next Data For Antidepressant Safety Review

Executive Summary

A 24,000-patient pediatric safety study currently under peer review could provide the next pool of data on the relationship between antidepressants and suicidality

You may also be interested in...



Pediatric Exclusivity Incentive May Encourage Sloppy Trials, FDA Says

The quality of pediatric research on antidepressants may have been affected by the need for manufacturers to complete trials in time to receive exclusivity extensions, FDA Office of Drug Evaluation I Acting Director Robert Temple, MD, suggested during the Sept. 13-14 advisory committee review of antidepressant safety

Pediatric Exclusivity Incentive May Encourage Sloppy Trials, FDA Says

The quality of pediatric research on antidepressants may have been affected by the need for manufacturers to complete trials in time to receive exclusivity extensions, FDA Office of Drug Evaluation I Acting Director Robert Temple, MD, suggested during the Sept. 13-14 advisory committee review of antidepressant safety

FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain

FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel